GlassScriptPhysician profile
David M Oberlin
NPI 1376924902
$102,896.51
in general payments reported to CMS, 2019-2025
32 companies · $95K in 2025
The $95K reported for 2025 was more than what 98% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $795 · 2020: $345 · 2021: $44.19 · 2022: $389 · 2023: $1,488 · 2024: $4,774 · 2025: $95K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $71K · Food and Beverage: $11K · Travel and Lodging: $9,902 · Consulting Fee: $9,750 · Education: $277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $70,700.00 |
| Food and Beverage | $10,694.64 |
| Travel and Lodging | $9,901.68 |
| Consulting Fee | $9,750.00 |
| Education | $276.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $43,160.63 | 2020-2025 | Otezla, Otezla |
| Abbvie INC. | $41,813.90 | 2019-2025 | |
| Ucb, INC. | $9,861.36 | 2019-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $1,200.95 | 2019-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $1,110.25 | 2019-2025 | Tremfya, Stelara, Remicade |
| Genzyme Corporation | $1,065.04 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $729.33 | 2020-2025 | Ilumya, Winlevi, Absorica Ld |
| Pfizer INC. | $586.47 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $516.10 | 2024-2025 | Zoryve |
| Incyte Corporation | $455.40 | 2022-2025 | Opzelura, Opzelura |
| E.R. Squibb & Sons, L.L.C. | $333.70 | 2023-2025 | Sotyktu |
| Organon LLC | $293.08 | 2024-2025 | Vtama, Hadlima |
| Galderma Laboratories, L.P. | $258.90 | 2024-2025 | Nemluvio |
| Novartis Pharmaceuticals Corporation | $258.80 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $200.49 | 2023-2025 | Spevigo, Cyltezo |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $186.11 | 2023 | Vtama |
| Leo Pharma INC. | $174.82 | 2023-2025 | Adbry, Anzupgo, Spevigo |
| Sanofi-Aventis U.S. LLC | $124.99 | 2019 | |
| Janssen Scientific Affairs, LLC | $122.60 | 2019 | |
| Allergan, INC. | $97.33 | 2019 | |
| Lilly USA, LLC | $73.07 | 2020-2024 | Taltz, Olumiant, Ebglyss |
| Fresenius Kabi USA, LLC | $67.99 | 2024 | Idacio |
| Dermira, INC. | $31.78 | 2020 | |
| Celgene Corporation | $30.78 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $28.23 | 2025 | Cabtreo |
| Lnhc, INC | $19.92 | 2025 | Zelsuvmi |
| Biofrontera INC. | $18.96 | 2020 | |
| Mayne Pharma Commercial LLC | $17.77 | 2019 | |
| Verrica Pharmaceuticals INC. | $15.02 | 2023 | Ycanth |
| Vyne Pharmaceuticals INC. | $14.86 | 2020 | |
| Helsinn Therapeutics (U.S.), INC. | $14.71 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Oberlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.